New research suggests that patients who discontinue popular slimming jabs like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who end traditional diet and exercise plans.
Findings released in a major medical journal points out that while obese people can lose a large proportion of their body weight while undergoing treatment, the weight returns at an average rate of nearly a kilo each month once they quit.
"Users using such treatments should be aware of the potential of quick weight regain when the therapy concludes," stated researcher Dr. Susan Jebb.
That rate of regain implies a reversion to starting weight in about a year and a half.
Comparing Approaches
The analysis, which examined dozens of studies involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
Scientists emphasize that individuals who shed pounds through diet and exercise typically see a slower creep back—approximately 100 grams monthly—once they finish.
Understanding the Quick Rebound
Nutrition scientists believe the mechanism of the jabs explains the amplified regain.
The injections copy a natural hormone called glucagon-like peptide-1, which controls appetite.
"Long-term administration of GLP-1 concentrations far above than the body's typical production may cause the system to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' results in appetite is unsuppressed, making overeating a significant risk."
A Lifelong Disease?
Health authorities recommend the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
Professionals contend that, given the likelihood of relapse, the treatment might need to be ongoing.
This perspective is reinforced by pharmaceutical companies, who note that the results "highlight the long-term nature of excess weight," similar to managing conditions like diabetes.
User Experiences
Individuals who have stopped the medication explain a sudden return of cravings.
"I experienced something that goes on and I was suddenly ravenous," recalled an individual.
This difficulty is compounded if patients have not developed permanent dietary or behavioural changes during treatment.
Significant Interest
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is greater among women compared to men.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Finally, clinicians emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent cure and long-term success likely depends on integrated lifestyle management.
